Table 2 Overall disposition
| Â | Sitagliptin 100 mg | Non-exposed |
|---|---|---|
RANDOMIZED, N | 5429 | 4817 |
| Â | n (%) | n (%) |
DISCONTINUED | 1818 (33.5) | 1694 (35.2) |
Reason for discontinuation | Â | Â |
   Adverse event | 239 (4.4) | 216 (4.5) |
   Lack of efficacy* | 614 (11.3) | 520 (10.8) |
   Lost to follow-up | 222 (4.1) | 180 (3.7) |
   Protocol violation | 98 (1.8) | 99 (2.1) |
   Protocol-specific criteria | 61 (1.1) | 55 (1.1) |
   Withdrawal of consent | 336 (6.2) | 367 (7.6) |
   Other reasons†| 248 (4.6) | 257 (5.3) |